EA201070585A1 - Композиции, содержащие антитела к vegf, и способы - Google Patents

Композиции, содержащие антитела к vegf, и способы

Info

Publication number
EA201070585A1
EA201070585A1 EA201070585A EA201070585A EA201070585A1 EA 201070585 A1 EA201070585 A1 EA 201070585A1 EA 201070585 A EA201070585 A EA 201070585A EA 201070585 A EA201070585 A EA 201070585A EA 201070585 A1 EA201070585 A1 EA 201070585A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
vegf
antibodies
compositions containing
containing antibodies
Prior art date
Application number
EA201070585A
Other languages
English (en)
Other versions
EA034136B1 (ru
Inventor
Анита Кавлье
Кайл Шлунеггер
Original Assignee
Перигрин Фармасьютикалз, Инк.
Аффитек Рисеч Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Перигрин Фармасьютикалз, Инк., Аффитек Рисеч Ас filed Critical Перигрин Фармасьютикалз, Инк.
Publication of EA201070585A1 publication Critical patent/EA201070585A1/ru
Publication of EA034136B1 publication Critical patent/EA034136B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описаны антитела человека, которые специфично ингибируют связывание VEGF лишь с одним (VEGFR2) из двух первично-чувствующих рецепторов VEGF. Указанные антитела эффективно ингибируют ангиогенез и индуцируют регрессию опухоли, а также обеспечивают повышенную безопасность вследствие их специфичности. В настоящем изобретении, таким образом, обеспечены новые основанные на антителах человека композиции, способы и комбинированные протоколы для лечения рака и других ангиогенных заболеваний. Также предусмотрены полезные иммуноконъюгатные композиции и способы, в которых применяются новые специфичные к VEGF антитела человека.
EA201070585A 2007-11-09 2008-11-07 Изолированное антитело, которое связывается с vegf, и его применения EA034136B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98701507P 2007-11-09 2007-11-09
US10604708P 2008-10-16 2008-10-16
US10802308P 2008-10-24 2008-10-24
PCT/GB2008/003745 WO2009060198A1 (en) 2007-11-09 2008-11-07 Anti-vegf antibody compositions and methods

Publications (2)

Publication Number Publication Date
EA201070585A1 true EA201070585A1 (ru) 2010-12-30
EA034136B1 EA034136B1 (ru) 2020-01-09

Family

ID=40428119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070585A EA034136B1 (ru) 2007-11-09 2008-11-07 Изолированное антитело, которое связывается с vegf, и его применения

Country Status (18)

Country Link
US (3) US8034905B2 (ru)
EP (2) EP2219672B1 (ru)
JP (2) JP5809415B2 (ru)
KR (2) KR20100102110A (ru)
CN (1) CN101918030B (ru)
AU (1) AU2008324045B2 (ru)
BR (1) BRPI0820298A8 (ru)
CA (1) CA2705152C (ru)
CO (1) CO6280498A2 (ru)
DK (1) DK2219672T3 (ru)
EA (1) EA034136B1 (ru)
ES (1) ES2572356T3 (ru)
HK (1) HK1147445A1 (ru)
IL (1) IL205547A (ru)
MX (1) MX2010005104A (ru)
NZ (1) NZ586053A (ru)
WO (1) WO2009060198A1 (ru)
ZA (2) ZA201003812B (ru)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166844A4 (en) * 2007-06-07 2013-09-04 Evonik Corp DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
EP2229951A1 (en) * 2009-03-08 2010-09-22 Stichting Katholieke Universiteit Methods for the treatment or prevention of systemic sclerosis
US20130309173A2 (en) * 2009-10-09 2013-11-21 SingaporeHealth Services Pte. Ltd. Methods and compositions for maintenance of a functional wound
EP2494062B1 (en) * 2009-10-28 2016-12-28 Janssen Biotech, Inc. Anti-glp-1r antibodies and their uses
EP3275898B1 (en) 2009-11-05 2024-06-05 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
CN102167740B (zh) * 2010-02-25 2014-06-04 上海百迈博制药有限公司 一种全人源抗vegf单克隆抗体、其制备方法及用途
EP2538965B1 (en) 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
US20130195757A1 (en) * 2010-04-30 2013-08-01 Abraxis Bioscience, Llc Sparc binding aptamers and uses thereof
EP3301176B1 (en) 2011-02-11 2019-09-25 The Rockefeller University Method for identifying nucleic acids regulating metastasation
WO2012154861A2 (en) 2011-05-09 2012-11-15 Mayo Foundation For Medical Education And Research Cancer treatments
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
CN102399868B (zh) * 2011-10-10 2013-01-30 江苏省农业科学院 一种猪tlr4基因t611a碱基突变的检测方法
JP6335875B2 (ja) * 2012-03-30 2018-05-30 ジェネンテック， インコーポレイテッド 癌の治療のための診断法及び組成物
WO2013149219A2 (en) * 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
CN103417965B (zh) * 2012-05-17 2018-04-13 江苏先声药业有限公司 一种含有抗vegf抗体的药物组合物
JP2015524441A (ja) * 2012-08-01 2015-08-24 テトラロジック ファーマシューティカルズ コーポレーション 併用療法
HUE046292T2 (hu) 2012-08-13 2020-02-28 Univ Rockefeller Melanóma kezelése és diagnosztizálása
EP3967306A1 (en) 2012-10-01 2022-03-16 Mayo Foundation for Medical Education and Research Cancer treatments
CN102863529A (zh) * 2012-10-09 2013-01-09 李彬 一种vegf单抗及包含该单抗的骨折愈合评价抗体芯片
CN104968216A (zh) 2012-12-10 2015-10-07 N·V·努特里奇亚 含有非消化性寡糖的营养组合物
WO2014118643A2 (en) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
RU2699007C2 (ru) 2013-02-18 2019-09-02 Ведженикс Пти Лимитед Молекулы, связывающие лиганды, и их применение
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
KR101541478B1 (ko) 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015070197A1 (en) * 2013-11-11 2015-05-14 Wake Forest University Health Sciences Detection of malignancy in brain cancer
US11020478B2 (en) 2013-11-27 2021-06-01 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
WO2015081290A1 (en) * 2013-11-27 2015-06-04 Inis Biotech Llc Methods for modulating angiogenesis of cancers refractory to anti-vegf treatment
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
GB201407852D0 (en) * 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3760229A3 (en) 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN104558175B (zh) * 2014-12-30 2017-02-22 安源医药科技（上海）有限公司 抗人vegf的重组嵌合抗体及其制备方法和用途
CN104530234B (zh) * 2014-12-30 2017-02-22 安源医药科技（上海）有限公司 检测人vegf的组合试剂、试剂盒及其使用方法
CN108148136B (zh) * 2015-01-06 2020-06-12 珠海亿胜生物制药有限公司 抗vegf抗体
CN108148133B (zh) * 2015-01-06 2020-04-24 珠海亿胜生物制药有限公司 抗vegf抗体
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
JP7228824B2 (ja) 2015-06-30 2023-02-27 国立大学法人大阪大学 抗プレキシンａ１アゴニスト抗体
JP2018522887A (ja) 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN106674352B (zh) * 2015-11-10 2020-05-15 孙嘉琳 抗肿瘤蛋白内皮抑素的衍生物及应用
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017141185A1 (en) * 2016-02-16 2017-08-24 The Regents Of The University Of California Methods and compositions for treating atherosclerosis
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHODS OF REDUCING THE TOXICITY OF A CHEMOTHERAPEUTIC MEDICAMENT
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
BR112018073781A2 (pt) 2016-05-20 2019-02-26 Biohaven Pharmaceutical Holding Company Ltd. uso de agentes de modulação de glutamato com imunoterapias para o tratamento de câncer
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
KR20230010817A (ko) 2016-09-06 2023-01-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 파클리탁셀-알부민-결합제 조성물 및 그의 사용 및 제조 방법
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
JP2019537619A (ja) 2016-09-27 2019-12-26 オンコロジー、インコーポレイテッド β２−糖タンパク質１のレベルに基づいて、バビツキシマブで癌を治療するための方法、およびそのためのアッセイ
JP2020515637A (ja) 2017-04-03 2020-05-28 オンコロジー、インコーポレイテッド 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法
JP7257335B2 (ja) 2017-05-25 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー アンタゴニスト性ｃｄ４０モノクローナル抗体およびその使用
US20210322574A1 (en) 2017-10-20 2021-10-21 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
EP3731864A1 (en) * 2017-12-29 2020-11-04 F. Hoffmann-La Roche SA Anti-vegf antibodies and methods of use
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
JP2021535206A (ja) * 2018-08-23 2021-12-16 バーンスタイン，エリック，エフ． 皮膚状態を治療するために抗ｖｅｇｆ化合物を適用するためおよびこのような化合物を使用するためのシステム、デバイスおよび方法
CN110885377B (zh) * 2018-09-11 2020-12-04 上海洛启生物医药技术有限公司 抗cd47/vegf双特异性抗体及其应用
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MX2021011084A (es) 2019-03-13 2021-10-22 Vascular Biogenics Ltd Metodos de terapia antitumoral.
EP4003508A1 (en) 2019-07-31 2022-06-01 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
EP4054635A4 (en) 2019-11-04 2023-12-06 Code Biotherapeutics, Inc. BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 1 (BAI1) ANTIBODIES AND USES THEREOF
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
TW202136188A (zh) 2019-12-13 2021-10-01 美商睿治尼斯公司 金屬鹽及其用途
CN111084879A (zh) * 2020-02-14 2020-05-01 中国人民解放军第四军医大学 白介素18在抑制创面血管新生中的应用
JP2024511166A (ja) 2021-03-25 2024-03-12 オンクセルナ セラピューティクス，インコーポレイテッド 癌の標的療法
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2182943A1 (en) 1972-04-10 1973-12-14 Rustenburg Platinum Mines Ltd Cis-dihalo-bis(ethyleneimine) platinum (ii) derivs - anti-cancer agents
CH605550A5 (ru) 1972-06-08 1978-09-29 Research Corp
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US5583013A (en) 1977-11-08 1996-12-10 Genentech, Inc. Method and means for microbial polypeptide expression
US5221619A (en) 1977-11-08 1993-06-22 Genentech, Inc. Method and means for microbial polypeptide expression
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4785420A (en) 1986-04-09 1988-11-15 Joyce Communications Systems, Inc. Audio/telephone communication system for verbally handicapped
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US5520914A (en) 1987-08-06 1996-05-28 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5183756A (en) 1988-08-19 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibody (D612) having selective reactivity for gastrointestinal caricinomas and method for employing the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
US5338678A (en) 1989-06-09 1994-08-16 Oncogen, A Limited Partnership Expression of DNA sequences encoding a thermally stable cytosine deaminase from saccharomyces
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5270196A (en) 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5972922A (en) 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5242813A (en) 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU648690B2 (en) 1991-07-03 1994-04-28 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
DK0627940T3 (da) 1992-03-05 2003-09-01 Univ Texas Anvendelse af immunokonjugater til diagnose og/eller terapi af vaskulariserede tumorer
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
GB9314960D0 (en) 1992-07-23 1993-09-01 Zeneca Ltd Chemical compounds
US5464833A (en) 1992-08-19 1995-11-07 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating composition
HUT72993A (en) 1992-08-19 1996-06-28 Merrell Dow Pharma Process to prepare phatmaceutical compns. contg antiangiogenic oligomers
WO1994007515A1 (en) 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5399586A (en) 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
WO1994028017A1 (en) 1993-06-01 1994-12-08 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9315494D0 (en) 1993-07-27 1993-09-08 Springer Caroline Improvements relating to prodrugs
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9323429D0 (en) 1993-11-12 1994-01-05 Wellcome Found Therapy
US5539094A (en) 1993-11-12 1996-07-23 La Jolla Cancer Research Foundation DNA encoding Bcl-2-associated proteins
US5622829A (en) 1993-12-08 1997-04-22 The Regents Of The University Of California Genetic markers for breast, ovarian, and prostatic cancer
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5840301A (en) 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5583034A (en) 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5591717A (en) 1994-04-06 1997-01-07 Rojko; Jennifer L. Branched apogenic peptide for inducing apoptosis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5618925A (en) 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
DE4417865A1 (de) 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5605826A (en) 1994-06-10 1997-02-25 Panorama Research, Inc. 24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
BR9508402A (pt) 1994-07-11 1997-10-21 Univ Texas Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5709999A (en) 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9426133D0 (en) 1994-12-23 1995-02-22 Zeneca Ltd Chemical compounds
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5571523A (en) 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
GB9510830D0 (en) 1995-05-27 1995-07-19 Zeneca Ltd Proteins
US5871723A (en) 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
US5750653A (en) 1995-06-07 1998-05-12 The Regents Of The University Of California Protein, FAF1, which potentiates Fas-mediated apoptosis and uses thereof
EP0751144B1 (en) 1995-06-27 2004-10-06 Pharmachemie B.V. Novel anthracycline prodrugs, method for preparation as well as their use in selective chemotherapy
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9517001D0 (en) 1995-08-18 1995-10-18 Denny William Enediyne compounds
US5756294A (en) 1995-09-25 1998-05-26 Oncormed, Inc. Susceptibility mutation for breast and ovarian cancer
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
EP0869818A1 (en) 1995-12-29 1998-10-14 AEPACT Limited Cytotoxic agents
GB9601640D0 (en) 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US5654155A (en) 1996-02-12 1997-08-05 Oncormed, Inc. Consensus sequence of the human BRCA1 gene
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
WO1999040118A1 (fr) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
WO2000002587A1 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005012531A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US7553496B2 (en) 2004-12-21 2009-06-30 University Of Kentucky Research Foundation VEGF-A as an inhibitor of angiogenesis and methods of using same
US8802442B2 (en) 2011-11-30 2014-08-12 Eric B. Wheeldon Apparatus and method for the remote sensing of blood in human feces and urine

Also Published As

Publication number Publication date
CA2705152C (en) 2016-10-11
HK1147445A1 (zh) 2011-08-12
US20090175791A1 (en) 2009-07-09
US20120064001A1 (en) 2012-03-15
US8034905B2 (en) 2011-10-11
IL205547A (en) 2016-03-31
BRPI0820298A8 (pt) 2018-05-08
KR101502267B1 (ko) 2015-03-18
MX2010005104A (es) 2010-08-04
KR20130136014A (ko) 2013-12-11
JP5809415B2 (ja) 2015-11-10
JP2011502503A (ja) 2011-01-27
IL205547A0 (en) 2010-12-30
CA2705152A1 (en) 2009-05-14
AU2008324045A1 (en) 2009-05-14
KR20100102110A (ko) 2010-09-20
ZA201106118B (en) 2012-11-28
WO2009060198A1 (en) 2009-05-14
EA034136B1 (ru) 2020-01-09
EP2219672B1 (en) 2016-02-17
US20130149238A1 (en) 2013-06-13
BRPI0820298A2 (pt) 2017-04-04
ZA201003812B (en) 2011-10-26
US8394943B2 (en) 2013-03-12
US9421256B2 (en) 2016-08-23
CN101918030B (zh) 2015-10-14
AU2008324045B2 (en) 2014-08-07
JP2015204830A (ja) 2015-11-19
EP2614837A1 (en) 2013-07-17
CO6280498A2 (es) 2011-05-20
NZ586053A (en) 2012-09-28
CN101918030A (zh) 2010-12-15
EP2219672A1 (en) 2010-08-25
DK2219672T3 (en) 2016-05-17
ES2572356T3 (es) 2016-05-31

Similar Documents

Publication Publication Date Title
EA201070585A1 (ru) Композиции, содержащие антитела к vegf, и способы
EA201170716A1 (ru) Антитела к с-мет
BR0010017A (pt) Composições e processos para o tratamento de câncer por inibição seletiva de vegf
EA201401107A1 (ru) Специфические антагонисты рецептора fgf-r4
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
EA201100923A1 (ru) Антитела человека против тканевого фактора
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
EA201691858A1 (ru) Композиции антител для лечения опухолей
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201170157A1 (ru) Notch-связывающие агенты и антагонисты и способы их применения
EA200970317A1 (ru) Комбинированное лечение опухолей, экспрессирующих cd38
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
CR9819A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos
MY151191A (en) Novel antibodies
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
EA201290104A1 (ru) Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
EA201171237A1 (ru) Антитела к dkk-1
CY1118254T1 (el) Αντισωματα toy βμρ-6
EA201992835A1 (ru) Противораковая комбинированная терапия
UA103012C2 (ru) Композиция, содержащая антитело к vegf, и способы ее применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM